Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population

NCT04852861 is registered in ClinicalTrials.gov with Sciensano as lead sponsor.

NCT NCT04852861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04852861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population
Lead sponsor
Sciensano
Phase
Phase 4
Overall status
Completed
Start date
May 10, 2021
Completion date
September 30, 2022
Enrollment
145 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19